If this message is not displayed correctly, click here.

FOR KIDNEY & BLOOD
PRESSURE RELATED
DISORDERS

An official publication of

NDT-Educational@ENP Newsletter

Issue 4 - April 2019

EDITOR IN CHIEF: Davide Bolignano

EDITORIAL BOARD: click here for the complete list

NEWSLETTER DESIGN: Francesca Trebelli

Summary Reports from 55^th ERA-EDTA Congress

Back from the future – Lowering oral steroids in lupus therapy

Presented by Guillermo Ruiz-Irastorza

Systemic lupus erythematosus (SLE) is a complex, systemic, autoimmune disease, involving a number of organs, including the kidneys. Renal involvement manifests as lupus nephritis (LN), which may eventually lead to kidney failure. Current treatment guidelines for LN suggest initial glucocorticoid (GC) treatment, with either 250 to 1000mg/day methylprednisone (MP) or 0.5 to 1mg/kg/day oral prednisone, depending whether combination with mycophenolate mofetil (MMF) or parenteral cyclophosphamide (CYC) is used. The tapering schedule, however, is still unclear. Recently published SLE treatment strategies by the British Society for Rheumatology also recommend high initial GC dosage, in either oral or pulse therapy, but aiming to reduce it to less than 7.5mg/day prednisone, or even eventually stop drugs when patient reaches stable remission. Still, the tapering regime also remains blurred.

Congress Presentation

This Congress talk has been presented by Guillermo Ruiz-Irastorza during the 55^th ERA-EDTA Congress in Copenhagen, Denmark.

View it here

Anti-GBM disease: New subgroups and novel therapies

Presented by Marten Segelmark

Anti-glomerular basement membrane (anti-GBM) disease, also known as Goodpasture’s disease, is an autoimmune vasculitis affecting glomerular capillaries, pulmonary capillaries, or both, with GBM deposition of anti-GBM autoantibodies.

In the early stage of the disease, most patients report some form of general prodromal symptoms such as fatigue and malaise that usually last a few weeks or months. The majority of patients (80%–90%) will present with features of rapidly progressive glomerulonephritis (GN). Forty percent to 60% of patients have concurrent lung hemorrhage, and a small number may present with isolated pulmonary disease. The incidence is approximately one per million of worldwide population per year.

Congress Presentation

This Congress talk has been presented by Marten Segelmark during the 55^th ERA-EDTA Congress in Copenhagen, Denmark.

View it here

References

Read this selection of articles about the two summary report fields.

Read the articles

New ERA-EDTA Dialogue!

Long-term graft survival in deceased kidney donors: how much importance should we give to HLA matching?

by Ana Carina Ferreira

Join the dialogue

Last weeks to comment these ERA-EDTA Dialogues!

Strawberries always fill my heart with joy (...and my kidneys with potassium): a clinical case study

by Björn Meijers

Join the dialogue

Potassium intake in CKD patients. Are we prescribing too much? Or too little? What is your taking?

by Pietro Manuel Ferraro

Join the dialogue

Incremental dialysis: from (limited) evidence to daily practice

by Mariusz Kusztal

Join the dialogue

Unsubscribe

The ERA-EDTA collects and processes personal information to provide you with details regarding the Association and its activities. The information is used for accounting and commercial purposes by ERA-EDTA and/or Euromeetings s.r.l. in compliance with the EU General Data Protection Regulation (2016/679).